TARRYTOWN, N.Y., Dec. 18,
2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
(NASDAQ: REGN) will webcast its presentation at the
37th Annual J.P. Morgan Healthcare Conference on
Monday, January 7, 2019. The
presentation is scheduled for 10:30 a.m.
Pacific Time (1:30 p.m. Eastern
Time) and may be accessed from the "Investors & Media"
page of Regeneron's website at
http://investor.regeneron.com/events.cfm. A breakout session will
immediately follow the formal presentation and can also be accessed
on our website. An archived version of the presentation and the
breakout session will be available for 30 days.
About Regeneron Pharmaceuticals, Inc.
Regeneron
(NASDAQ: REGN) is a leading biotechnology company that invents
life-transforming medicines for people with serious diseases.
Founded and led for 30 years by physician-scientists, our unique
ability to repeatedly and consistently translate science into
medicine has led to seven FDA-approved treatments and numerous
product candidates in development, all of which were homegrown in
our laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, neuromuscular
diseases, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary
VelociSuite® technologies, such as
VelocImmune® which produces optimized fully-human
antibodies, and ambitious research initiatives such as the
Regeneron Genetics Center, which is conducting one of the largest
genetics sequencing efforts in the world.
For additional information about the company, please visit
www.regeneron.com or follow @Regeneron on Twitter.
Contact Information:
Investor Relations
Mark Hudson
914-847-3482
mark.hudson@regeneron.com
Corporate Communications
Alexandra Bowie
914-847-3407
alexandra.bowie@regeneron.com
View original
content:http://www.prnewswire.com/news-releases/regeneron-announces-presentation-at-the-37th-annual-jp-morgan-healthcare-conference-300768286.html
SOURCE Regeneron Pharmaceuticals, Inc.